Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP892988.RAZgL5AKSb84Zd3__ChdVxw3bB-Ws_Mby7p4hN_XIRIto130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP892988.RAZgL5AKSb84Zd3__ChdVxw3bB-Ws_Mby7p4hN_XIRIto130_assertion type Assertion NP892988.RAZgL5AKSb84Zd3__ChdVxw3bB-Ws_Mby7p4hN_XIRIto130_head.
- NP892988.RAZgL5AKSb84Zd3__ChdVxw3bB-Ws_Mby7p4hN_XIRIto130_assertion description "[The PC-3 tumor cell line has an elevated expression of GRP-Rs (2.5 x 10(5)/cell), whereas LNCaP--a prostate cancer metastatic cell line representing the early androgen-sensitive stage of prostate cancer--and DU145--an androgen-insensitive metastatic line--express lower receptor numbers (5.9 x 10(3) and 1.2 x 10(4)/cell, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP892988.RAZgL5AKSb84Zd3__ChdVxw3bB-Ws_Mby7p4hN_XIRIto130_provenance.
- NP892988.RAZgL5AKSb84Zd3__ChdVxw3bB-Ws_Mby7p4hN_XIRIto130_assertion evidence source_evidence_literature NP892988.RAZgL5AKSb84Zd3__ChdVxw3bB-Ws_Mby7p4hN_XIRIto130_provenance.
- NP892988.RAZgL5AKSb84Zd3__ChdVxw3bB-Ws_Mby7p4hN_XIRIto130_assertion SIO_000772 19910427 NP892988.RAZgL5AKSb84Zd3__ChdVxw3bB-Ws_Mby7p4hN_XIRIto130_provenance.
- NP892988.RAZgL5AKSb84Zd3__ChdVxw3bB-Ws_Mby7p4hN_XIRIto130_assertion wasDerivedFrom befree-20150227 NP892988.RAZgL5AKSb84Zd3__ChdVxw3bB-Ws_Mby7p4hN_XIRIto130_provenance.
- NP892988.RAZgL5AKSb84Zd3__ChdVxw3bB-Ws_Mby7p4hN_XIRIto130_assertion wasGeneratedBy ECO_0000203 NP892988.RAZgL5AKSb84Zd3__ChdVxw3bB-Ws_Mby7p4hN_XIRIto130_provenance.